ÂÜÀòÂÒÂ×

Michael Covington has a strong work experience in the biotechnology and pharmaceutical industry. Michael is currently the Chief Quality and Regulatory Officer at Landmark Bio since October 2021.

Previously, they served as the Vice President of Regulatory CMC at Novartis Gene Therapies from August 2020 to October 2021 and at Orchard Therapeutics from May 2019 to August 2020.

Prior to that, Michael held multiple roles at Juno Therapeutics, including Principal of CMC Regulatory Policy and Strategy from June 2015 to May 2019 and Vice President of Regulatory Affairs and Quality from October 2013 to May 2015.

Before their time at Juno Therapeutics, they held senior positions at Dendreon, where they served as the Senior Director of Global Regulatory Affairs from May 2010 to October 2013 and the Senior Director of Quality Assurance from 2003 to April 2010.

Michael started their career at Amgen in 1993 as a Senior Manager of Validation and worked there until joining Dendreon in 2003. Michael began their professional journey as a Research Biologist at Monsanto in 1988. Overall, Michael Covington has amassed a wealth of experience in regulatory affairs, quality, and CMC policy and strategy throughout their career.

Michael Covington attended the University of Missouri-Columbia from 1984 to 1988, where they pursued a Bachelor's degree in Biology with a focus on Cellular and Molecular Biology.